{"name":"Prometic Biotherapeutics, Inc.","slug":"prometic-biotherapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ryplazim","genericName":"Ryplazim","slug":"ryplazim","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Ryplazim","genericName":"Ryplazim","slug":"ryplazim","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1BcnlYOWdmV3Uwb3diZEQyVW1VcWJBdVNuQkJFSVFtNHBUSEdGYTFBY1RBYURiNkhfWjBFV184bTdldk1NQ3Z5TVVFV0ZNWlFCTFgyNXk0b3YwR0xfMXhaRlFLWVp2clZ4TjZ5RTdBTXdlbmNy?oc=5","date":"2025-03-24","type":"pipeline","source":"Straits Research","summary":"Scleroderma Therapeutics Market Size, Top Share, Global Trends And Forecast to 2033 - Straits Research","headline":"Scleroderma Therapeutics Market Size, Top Share, Global Trends And Forecast to 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFB5Sjlhd3RFUklQVURmYWpqc1ltQ3FqWjJmd05Zak51VHEwTHJ5Z0dlS0RoU1VzX1IwZGF3Y0Zubno3MVJMZ2JqTjE3VTZxQzJ2X211Z01hWVFUYXRscFVrelNHSDRZQlNvSnVHdmoxQ3V4cER0?oc=5","date":"2025-01-15","type":"pipeline","source":"Precedence Research","summary":"Scleroderma Therapeutics Market Size to Surpass USD 5.04 Billion by 2035 - Precedence Research","headline":"Scleroderma Therapeutics Market Size to Surpass USD 5.04 Billion by 2035","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AJBVV95cUxOcWdtWlF4SU1sUzlOOXlKU2g1Yjh6YlYzS0ZYSlFuZHhubDhYd19Cc0V2NUFEcXlSeURLbkVzSHBSaWFEWFRKVnJKbFpkby1pa3VGR3k3UHlnOF9Gd1NlTk55WmlsQ0FMLTU4ZWNkUmF0azVRVGJYTnlaQ2g4bFFVeVI3djFZWXBNZ1BMT0MwTlVfdUZMeEZ6SW1pak1udWFHUldYLU9pemh2b0YxSGttRnBoZnd6SU9TOVl1cjAwcHRSaDRxSEQzaVBmVnFNdDFQMzhFRVNrOU9ONEdLTHB6ZDE3aGtqNTNRdF8tYXJYNWQ4cnRCVTR2cUtfa0IxVDZWa3FRa0h0UFUxMVJ5bFF0aVYybjNzb29nTWJISVEyU1g3aVhzSjRQNlV1cjJkV2FKRmd3TVVmR24wWjRrWUxOLXh6X1NqUmVMUUNIZFFxdEJTZ1ZoZmN6TFRVaWN3U0huc2tNdQ?oc=5","date":"2024-03-13","type":"deal","source":"businesswire.com","summary":"Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and Milestone Payments for Deals Signed Since 2020 - ResearchAndMarkets.com - busin","headline":"Pharmaceutical and Biotechnology Royalty Rates Report and Directory 2024: Technology Licensed, License Fees, Upfront and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE1lQzBHZllROXdvNktCRUhuRURvM3pTdnAyN1hNb1RTR3Q4WlR6SERBcHJDX3NfQWlRT2ZwbDlMX2ljX19ReTZERWlaZU04Wllxb0ZCTVdEbXNhX1FyaWZwbjQ1SQ?oc=5","date":"2023-09-18","type":"trial","source":"Wiley Online Library","summary":"Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis - Wiley Online Library","headline":"Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed no","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxOczlGRldJdG1oOEpETWFOc3lQaGdOODhRa3ZMT0dvN2lTU2NUOGhkM2VWZXpDd3hDLTM0aGpoZXdsWS05SDdBM1RrQ3JyMDMza0NPNy1nYVUtaXdjUmtfUWlNUnU1RnpYSkZxY2t3SzRjRmZRM0ZHbzU4QnY5VFBBTVhyaXRRVXc2ME45Rmk5ZWZzdThpS1JTQ1o3OFB1RmNiMkJadGczWXR3VmthTjg2TXZCYjB2b2Q4b3gtQkx1cldieDFPR2NrWm9QODA5MVAyTHVPXzM1Z3ZqOUp1aVBBM3RRVlRpcjRmcjZOUkFzcEVBMkVrcm9tY0RDa3pSaDRyMU5wZHFUcHEtVk04VXdocmQ4My1IRGk1TG85aVFDOU4zS1phYVpwaF9LOGtQYXZtSHNvSmpsUXdDMGxOcXNUdE5wTzJCMjg?oc=5","date":"2022-01-21","type":"deal","source":"BeBeez International","summary":"It’s official, Permira strikes control of leading plasma derivatives maker Kedrion and British competitor BPL. Together with ADIA. The Marcucci family and FSI fund to reinvest in the deal. Cdp Equity ","headline":"It’s official, Permira strikes control of leading plasma derivatives maker Kedrion and British competitor BPL. Together ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQdlhtdUFkSFpuc2dpNzBheWhfcndsa2hwdmIydHhOZEROMlo5bDNuQk15ak1oWmpTbUFlUEpXYV85RVp1SmZjVGh1Q1NyNTZ4X3RUVmI1emNSYk5yTnBBaktPaG9LUmNYWDNTNERvNlJvaTlQbDFxYlIxMXRKTVQxVFljNTJFNUJONWthSVNsQldDMUMxRENFREhJSXFEVV9uUk5KYXczemtZUzdCRG5fRVJmWC1IclUxVmlfTVFwUkh6bThuZFVGbWhTV2tZMmNpUTI4?oc=5","date":"2021-10-18","type":"pipeline","source":"prnewswire.com","summary":"Kedrion Biopharma grows in North America as it completes acquisition of Prometic - prnewswire.com","headline":"Kedrion Biopharma grows in North America as it completes acquisition of Prometic","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}